Raymond Chee Hui Ng
Overview
Explore the profile of Raymond Chee Hui Ng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan S, Goh L, Ong B, Ng D, Lin L, Ng R, et al.
Pharmacoecon Open
. 2024 Jul;
8(5):679-688.
PMID: 39042227
Background: Healthcare sustainability is a global challenge. Various value-driven healthcare strategies have been implemented by Singapore's national health technology assessment (HTA) agency, the Agency for Care Effectiveness (ACE). Considering the...
2.
Khor C, Winter S, Sutiman N, Murdter T, Chen S, Lim J, et al.
Clin Pharmacol Ther
. 2023 Jan;
113(3):712-723.
PMID: 36629403
The therapeutic efficacy of tamoxifen is predominantly mediated by its active metabolites 4-hydroxy-tamoxifen and endoxifen, whose formation is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Yet, known CYP2D6 polymorphisms...
3.
Kong S, Liu X, Tan S, Tai J, Phua L, Poh H, et al.
Front Oncol
. 2021 Aug;
11:698551.
PMID: 34336686
Introduction: Circulating tumor cells (CTCs) and cell-free tumor DNA (ctDNA) are tumor components present in circulation. Due to the limited access to both CTC enrichment platforms and ctDNA sequencing in...
4.
Yap N, Tan N, Tan C, Loh K, Ng R, Ho H, et al.
Breast Cancer Res Treat
. 2020 Jul;
183(3):683-696.
PMID: 32696315
Purpose: Brain-derived neurotrophic factor (BDNF) and the BDNF Val66Met polymorphism (rs6265) have been implicated in neurodegenerative conditions. This study aimed to investigate the associations of plasma BDNF and rs6265 with...
5.
Yap Y, Leong M, Chua Y, Loh K, Lee G, Lim E, et al.
PLoS One
. 2019 Sep;
14(9):e0221305.
PMID: 31553731
Objectives: We aimed to study the prevalence of CTCs in breast cancer (BC) patients undergoing neoadjuvant or palliative therapy with a label-free microfluidic platform (ClearCell FX), and its prognostic relevance...
6.
Tan C, Lim S, Toh Y, Ng T, Yeo A, Shwe M, et al.
Mol Neurobiol
. 2018 Nov;
56(7):4741-4750.
PMID: 30382534
Cancer-related cognitive impairment (CRCI) adversely affects cancer patients. We had previously demonstrated that the BDNF Val66Met genetic polymorphism is associated with lower odds of subjective CRCI in the multitasking and...
7.
Chan C, Munusamy P, Loke S, Koh G, Yang A, Law H, et al.
Oncotarget
. 2018 Mar;
9(16):12796-12804.
PMID: 29560110
Genome-wide association studies (GWAS) have proven highly successful in identifying single nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk. The majority of these studies are on European populations, with...
8.
Yap Y, Kwok L, Syn N, Chay W, Chia J, Tham C, et al.
JAMA Oncol
. 2017 Jul;
3(11):1538-1545.
PMID: 28715540
Importance: Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective: To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving...
9.
Sutiman N, Lim J, Muerdter T, Singh O, Cheung Y, Ng R, et al.
Clin Pharmacokinet
. 2016 Apr;
55(10):1239-1250.
PMID: 27098059
Tamoxifen (TAM) is an established endocrine treatment for all stages of oestrogen receptor (ER)-positive breast cancer. Its complex metabolism leads to the formation of multiple active and inactive metabolites. One...
10.
Lim J, Sutiman N, Muerdter T, Singh O, Cheung Y, Ng R, et al.
Br J Clin Pharmacol
. 2016 Jan;
81(6):1142-52.
PMID: 26799162
Aim: The aim was to examine the influence of CYP2C19 variants and associated haplotypes on the disposition of tamoxifen and its metabolites, particularly norendoxifen (NorEND), in Asian patients with breast...